Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;6(6):e397-e408.
doi: 10.1016/S2665-9913(23)00300-4. Epub 2024 Apr 1.

Large vessel giant cell arteritis

Affiliations
Review

Large vessel giant cell arteritis

Kornelis S M van der Geest et al. Lancet Rheumatol. 2024 Jun.

Abstract

Giant cell arteritis is the principal form of systemic vasculitis affecting people over 50. Large-vessel involvement, termed large vessel giant cell arteritis, mainly affects the aorta and its branches, often occurring alongside cranial giant cell arteritis, but large vessel giant cell arteritis without cranial giant cell arteritis can also occur. Patients mostly present with constitutional symptoms, with localising large vessel giant cell arteritis symptoms present in a minority of patients only. Large vessel giant cell arteritis is usually overlooked until clinicians seek to exclude it with imaging by ultrasonography, magnetic resonance angiography (MRA), computed tomography angiography (CTA), or [18F]fluorodeoxyglucose-PET-CT. Although the role of imaging in treatment monitoring remains uncertain, imaging by MRA or CTA is crucial for identifying aortic aneurysm formation during patient follow up. In this Series paper, we define the large vessel subset of giant cell arteritis and summarise its clinical challenges. Furthermore, we identify areas for future research regarding the management of large vessel giant cell arteritis.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests KSMvdG reports a grant from FOREUM Foundation for Research in Rheumatology, speaker fees from Roche, and research support from AbbVie, all outside the submitted work and paid to the University Medical Center Groningen (UMCG). TAB reports research grants from Deutsche Forschungsgemeinschaft and Siemens Healthineers paid to his institution and personal consulting fees and honoraria for lectures from Bracco, BTR, Guerbet, Siemens Healthineers, Novartis, and Roche. RHJAS reports independent research grants from Siemens Healthineers and Pfizer. EB, as an employee of the UMCG, received grants from the Dutch Arthritis Society and the EU, European Federation of Pharmaceutical Industries and Associations, and Innovative Medicines Initiative 2 Joint Undertaking Immune-Image (grant no 831514), which were paid to the UMCG. All other authors declare no competing interests.

MeSH terms

LinkOut - more resources